Skip to content Skip to navigation

Ali Khademhosseini

March 1, 2019 - 3:00pm
McCullough 115

Emerging Organ Models and Organ Printing for Regenerative Medicine

Ali Khademhosseini

Department of Bioengineering, Chemical Engineering, Radiology
University of California-Los Angeles (UCLA)

Abstract:

Engineered materials that integrate advances in polymer chemistry, nanotechnology, and biological sciences have the potential to create powerful medical therapies. Our group aims to engineer tissue regenerative therapeutics using water-containing polymer networks called hydrogels that can regulate cell behavior. Specifically, we have developed photo-crosslinkable hybrid hydrogels that combine natural biomolecules with nanoparticles to regulate the chemical, biological, mechanical and electrical properties of gels. These functional scaffolds induce the differentiation of stem cells to desired cell types and direct the formation of vascularized heart or bone tissues. Since tissue function is highly dependent on architecture, we have also used microfabrication methods, such as microfluidics, photolithography, bioprinting, and molding, to regulate the architecture of these materials. We have employed these strategies to generate miniaturized tissues. To create tissue complexity, we have also developed directed assembly techniques to compile small tissue modules into larger constructs. It is anticipated that such approaches will lead to the development of next-generation regenerative therapeutics and biomedical devices.

Bio:

Ali Khademhosseini is the Levi Knight Professor of Bioengineering, Chemical Engineering and Radiology and the Founding Director of the Center for Minimally Invasive Therapeutics at University of California-Los Angeles (UCLA). He joined UCLA in Nov. 2017 from Harvard University where he was Professor of Medicine at Harvard Medical School (HMS), and a faculty at Harvard-MIT Health Sciences and Technology and the Wyss Institute. At Harvard, he directed the Biomaterials Innovation Research Center (BIRC) a world renown bioengineering initiative which comprised of over 100 researchers.

He is a leader in applying bioengineering solutions to precision medicine. His large and interdisciplinary group is interested in developing ‘personalized’ solutions that utilize micro- and nanoscale technologies to enable a range of therapies for organ failure, cardiovascular disease and cancer. For example, he has developed numerous techniques in controlling the behavior of patient-derived cells to engineer artificial tissues and cell-based therapies. He is also developing ‘organ-on-a-chip’ systems that aim to mimic human physiology and pathology to enable patient-specific evaluation of drug candidates. In addition, his laboratory is a leader in utilizing 3D bioprinting to form vascularized tissues as well as to direct stem cell differentiation. He has also pioneered various high-performance biomaterials that can respond to each patient’s needs.

He has authored >550 journal papers and 60 books/chapters. He is one of the most cited young faculty in the world with >40,000 citations and H-index >100. In addition, he has delivered 300+ invited/keynote lectures. Dr. Khademhosseini’s interdisciplinary research has been recognized by over 50 major national and international awards. Every year since 2014 he has been recognized by Thomson Reuters in their list of the worlds most influential minds. In 2016, he received the Sr. Scientist Award of Tissue Engineering and Regenerative Medicine Society -Americas Chapter (TERMIS-AM) and in 2017 he received the Clemson Award of the Society for Biomaterials. He is also a recipient of the Presidential Early Career Award for Scientists and Engineers. He is an elected member of the Canadian Academy of Engineering, and a fellow of various organizations including the American Institute for Medical and Biological Engineering (AIMBE), Materials Research Society (MRS), Biomedical Engineering Society (BMES), Royal Society of Chemistry (RSC), Biomaterials Sciences and Engineering (FBSE) and American Association for the Advancement of Science (AAAS). Currently he serves on the editorial board of numerous leading journals as well as an Associate Editor for ACS Nano (IF: 13.3). He received his Ph.D. in bioengineering from MIT (2005), and MASc (2001) and BASc (1999) degrees from University of Toronto both in chemical engineering. Read more at: http://www.tissueeng.net/lab

This event belongs to the following series